Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
{{output}}
Background: Immune checkpoint inhibitors (ICIs) are standard therapy for unresectable HCC, but many patients do not respond. Non-viral HCC, particularly non-alcoholic steatohepatitis (NASH), have been implicated in ICI resistance... ...
